Defining Mechanisms of Sensitivity and Resistance to Histone Deacetylase Inhibitors to Develop Effective Thereaputic Strategies for the Treatment of Aggressive Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma (NHL). The current standard of care is the combination of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but this only results in a 60% over-all 5-year survival rate, thus highli...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
The University of Arizona.
2016
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10150/622977 http://arizona.openrepository.com/arizona/handle/10150/622977 |